Once the news of the FDA’s action against 23andMe came out, it was only a matter of time before stories of errors using the service surfaced. This particular story is very interesting because of how deep this person went to identify the problem–dowloading the raw 23andMe data, using other pieces of software to parse it, and ultimately discovering he DID have two mutations for limb-girdle muscular dystrophy but they were on two different genes.

Do stories like this put the FDA in the right? Should 23andMe be shutdown for good? Do we need to end the pursuit of direct-to-consumer genomics services? It’s unclear right now. These are complicated issues which require time and thought before settling on a path to find answers.